So far, so good with IPOs but Douglas and Galderma must work
Risk appetite is back and more deals coming, though one bad IPO would damage confidence in the recovery
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts